|
PL192364B1
(pl)
*
|
1998-06-08 |
2006-10-31 |
Hoffmann La Roche |
Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
CZ301182B6
(cs)
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
|
|
US7208167B2
(en)
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
|
DE60125377T2
(de)
*
|
2000-08-07 |
2007-09-27 |
Sciclone Pharmaceuticals, Inc., San Mateo |
Behandlung von hepatitis c mit thymosin, interferon und ribavirin
|
|
US7179791B2
(en)
|
2001-01-11 |
2007-02-20 |
Duke University |
Inhibiting GS-FDH to modulate NO bioactivity
|
|
WO2003026589A2
(en)
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
|
TW200500375A
(en)
|
2002-06-28 |
2005-01-01 |
Idenix Cayman Ltd |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
|
|
WO2004002422A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
ES2624353T3
(es)
*
|
2002-11-15 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
|
|
RU2005121904A
(ru)
|
2002-12-12 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
Способ получения 2`-разветвленных нуклеозидов
|
|
JP2006514038A
(ja)
*
|
2002-12-23 |
2006-04-27 |
イデニクス（ケイマン）リミテツド |
３’−ヌクレオシドプロドラッグの生産方法
|
|
EP4032897B1
(en)
|
2003-05-30 |
2025-01-29 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
|
US8615282B2
(en)
|
2004-07-13 |
2013-12-24 |
Dexcom, Inc. |
Analyte sensor
|
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
EP2899277A1
(en)
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
CN101242857A
(zh)
*
|
2005-08-15 |
2008-08-13 |
弗·哈夫曼-拉罗切有限公司 |
用于HBV治疗的PEG-IFNa和利巴韦林
|
|
US9201979B2
(en)
*
|
2005-09-14 |
2015-12-01 |
Millennial Media, Inc. |
Syndication of a behavioral profile associated with an availability condition using a monetization platform
|
|
JP5254033B2
(ja)
*
|
2005-12-23 |
2013-08-07 |
イデニク プハルマセウティカルス，インコーポレイテッド |
分岐型ヌクレオシドを調製するための合成中間体の製造方法
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
EP2313430B1
(en)
|
2008-06-24 |
2018-05-02 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
|
WO2010033443A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Boehringer Ingelheim International Gmbh |
Combination of hcv ns3 protease inhibitor with interferon and ribavirin
|
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
ES2537785T3
(es)
|
2009-05-08 |
2015-06-12 |
Sciclone Pharmaceuticals, Inc. |
Péptidos de alfa timosina como potenciadores de vacunas
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
CN102612362A
(zh)
|
2009-08-05 |
2012-07-25 |
皮里斯股份公司 |
脂质运载蛋白突变蛋白的控制释放制剂
|
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
|
US9549968B2
(en)
|
2009-12-07 |
2017-01-24 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
|
|
JP2013527145A
(ja)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
リン含有活性化剤の立体選択的合成
|
|
SMT201900297T1
(it)
|
2010-06-08 |
2019-07-11 |
Astrazeneca Ab |
Muteine di lipocalina lacrimale che si legano a il-4 r alfa
|
|
CA2808392C
(en)
|
2010-08-16 |
2020-03-10 |
Pieris Ag |
Binding proteins for hepcidin
|
|
DK2640740T3
(en)
|
2010-11-15 |
2017-06-26 |
Pieris Pharmaceuticals Gmbh |
MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
|
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
|
US9221885B2
(en)
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
|
CA2840242C
(en)
|
2011-09-16 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
SG10201604566QA
(en)
|
2011-12-13 |
2016-07-28 |
Pieris Ag |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
|
US20140039923A1
(en)
*
|
2012-08-03 |
2014-02-06 |
AxelaCare Health Solutions, Inc. |
Computer program, method, and system for receiving and managing patient data gathered during patient treatments
|
|
KR20200060782A
(ko)
|
2013-01-31 |
2020-06-01 |
길리애드 파마셋 엘엘씨 |
두 항바이러스 화합물의 병용 제형물
|
|
CA2905186A1
(en)
|
2013-03-14 |
2014-09-18 |
Daiichi Sankyo Co., Ltd |
Novel binding proteins for pcsk9
|
|
CA2891557A1
(en)
|
2013-03-26 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
EP3650014B1
(en)
|
2013-08-27 |
2021-10-06 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
CN113621050A
(zh)
|
2014-05-22 |
2021-11-09 |
皮里斯制药有限公司 |
新型特异性结合多肽及其用途
|
|
SG10201906859PA
(en)
|
2015-01-28 |
2019-08-27 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for angiogenesis
|
|
AR103714A1
(es)
|
2015-02-18 |
2017-05-31 |
Sanofi Sa |
Proteínas específicas para pioverdina y pioquelina
|
|
US11261221B2
(en)
|
2015-05-04 |
2022-03-01 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for CD137
|
|
CN107636014B
(zh)
|
2015-05-04 |
2021-12-07 |
皮里斯制药有限公司 |
抗癌融合多肽
|
|
FI3298030T3
(fi)
|
2015-05-18 |
2023-02-22 |
Pieris Pharmaceuticals Gmbh |
Syöpää ehkäisevä fuusiopolypeptidi
|
|
CN107787327B
(zh)
|
2015-05-18 |
2022-02-08 |
皮里斯制药有限公司 |
对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
|
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
|
CN108348573A
(zh)
|
2015-07-15 |
2018-07-31 |
皮里斯制药有限公司 |
Lag-3特异性的新型蛋白
|
|
SG11201803732PA
(en)
|
2015-11-30 |
2018-06-28 |
Pieris Australia Pty Ltd |
Novel anti-angiogenic fusion polypeptides
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
MX2019008434A
(es)
|
2017-01-18 |
2019-11-11 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina con afinidad de unión por lag-3.
|
|
AU2019315703A1
(en)
|
2018-07-31 |
2020-12-10 |
Les Laboratoires Servier |
Novel fusion protein specific for CD137 and PD-L1
|
|
US12486330B2
(en)
|
2019-02-26 |
2025-12-02 |
Pieris Pharmaceuticals Gmbh |
Fusion proteins specific for CD137 and GPC3
|
|
CN116249709A
(zh)
|
2020-06-05 |
2023-06-09 |
皮里斯制药有限公司 |
靶向4-1bb的多聚体免疫调节剂
|
|
EP4320141A1
(en)
|
2021-04-08 |
2024-02-14 |
Pieris Pharmaceuticals GmbH |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
TW202428603A
(zh)
|
2022-09-21 |
2024-07-16 |
美商思進公司 |
新穎的cd137及cd228特異性融合蛋白
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|